BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6695631)

  • 1. Therapeutic results with a new ergoline derivate (8-alpha-amino-ergoline, CU 32-085) in parkinsonian patients.
    Schneider E; Hubener K; Fischer PA
    Adv Neurol; 1984; 40():527-9. PubMed ID: 6695631
    [No Abstract]   [Full Text] [Related]  

  • 2. CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.
    Rascol O; Fabre N; Teräväinen H; Poewe W; Lücking C; Rinne U; Dupont E; Hirt D; Hoyer M; Lataste X
    Clin Neuropharmacol; 1990 Aug; 13(4):303-11. PubMed ID: 2208182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Parkinson's disease with 8-alpha-amino-ergoline, CU 32-085.
    Schneider E; Hubener K; Fischer PA
    Neurology; 1983 Apr; 33(4):468-72. PubMed ID: 6682193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesulergine (CU32-085) in the treatment of Parkinson's disease.
    Pfeiffer RF; Wilken K; Glaeske C
    Ann Neurol; 1985 Apr; 17(4):334-6. PubMed ID: 3890700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bromocriptine and lisuride in Parkinson's disease.
    Caraceni T; Giovannini P; Parati E; Scigliano G; Grassi MP; Carella F
    Adv Neurol; 1984; 40():531-5. PubMed ID: 6695632
    [No Abstract]   [Full Text] [Related]  

  • 6. Pergolide in late-stage Parkinson disease.
    Lang AE; Quinn N; Brincat S; Marsden CD; Parkes JD
    Ann Neurol; 1982 Sep; 12(3):243-7. PubMed ID: 6753730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
    Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
    Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic experience with the new dopamine agonist CU 32-085 in advanced Parkinson's disease.
    Biesemeyer H; Ludin HP; Ringwald E
    J Neurol; 1983; 230(1):19-23. PubMed ID: 6194269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Long term evaluation of combined treatment of Parkinson disease with L-dopa, peripheral decarboxylase inhibitors and bromocreptine".
    Caraceni T; Giovannini P; Girotti F; Parati E; Pederzoli M; Scigliano G
    Ital J Neurol Sci; 1981 Dec; 2(4):337-42. PubMed ID: 7333824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromocriptine and lisuride in Parkinson disease.
    Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Walker R; Hiesiger E
    Ann Neurol; 1983 Jan; 13(1):44-7. PubMed ID: 6830164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Oral lisuride in Parkinson's disease].
    Obeso JA; Luquin MR; Martínez Lage JM
    Med Clin (Barc); 1985 Sep; 85(8):307-12. PubMed ID: 4068822
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effect of lisuride in the "on-off" phenomena due to L-dopa].
    Piccinin GL; Piccirilli M; Rizzo PA; Agostini L
    Clin Ter; 1983 Mar; 104(6):469-71. PubMed ID: 6851447
    [No Abstract]   [Full Text] [Related]  

  • 13. Placebo-controlled study of mesulergine in Parkinson's disease.
    Jankovic J; Orman J; Jansson B
    Neurology; 1985 Feb; 35(2):161-5. PubMed ID: 3881692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pergolide in the treatment of Parkinson's disease.
    Quinn NP; Lang AE; Thompson C; Brincat S; Marsden CD; Parkes JD
    Adv Neurol; 1984; 40():509-13. PubMed ID: 6695628
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of pergolide and mesulergine.
    Lieberman AN; Gopinathan G; Neophytides A
    Eur Neurol; 1986; 25(2):86-90. PubMed ID: 3948891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical study of pergolide in Parkinson's disease].
    Gonce M; Delwaide PJ
    Presse Med; 1985 Jun; 14(26):1409-11. PubMed ID: 3161045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low CSF GABA in Parkinsonian patients who respond poorly to therapy or suffer from the "on-off" phenomenon.
    Teychenné PF; Ziegler MG; Lake CR; Enna SJ
    Ann Neurol; 1982 Jan; 11(1):76-9. PubMed ID: 6120678
    [No Abstract]   [Full Text] [Related]  

  • 18. Long term bromocriptine treatment in de novo parkinsonian patients.
    Herskovits E; Yorio A; Leston J
    Medicina (B Aires); 1988; 48(4):345-50. PubMed ID: 3076200
    [No Abstract]   [Full Text] [Related]  

  • 19. Finasteride attenuates pathological gambling in patients with Parkinson disease.
    Bortolato M; Cannas A; Solla P; Bini V; Puligheddu M; Marrosu F
    J Clin Psychopharmacol; 2012 Jun; 32(3):424-5. PubMed ID: 22534502
    [No Abstract]   [Full Text] [Related]  

  • 20. Pergolide treatment in parkinsonism.
    Ilson J; Fahn S; Mayeux R; Cote LJ; Snider SR
    Adv Neurol; 1983; 37():85-94. PubMed ID: 6858780
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.